EUVIMEDEUVIMED entdecken
Crossref

GLP-1 Receptor Agonists in Preconception Management of Obese Women with Polyendocrine Metabolic Ovarian Syndrome (PMOS): Metabolic and Reproductive Implications

Turan Kaan Karakaya, Sercan Yılmaz

Cerasus Journal of Medicine · 31.05.2026 · 3 (2) · 157-164

DOI: 10.70058/cjm.1924573 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cerasus Journal of Medicine, online erschienen am 31.05.2026. Verfasst von Turan Kaan Karakaya und 1 weiteren Autor:innen. Die Arbeit nennt 16 Literaturangaben. Gefördert von: This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

To evaluate the impact of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) on metabolic parameters, hormonal profiles, and reproductive outcomes in the preconception management of women with polyendocrine metabolic ovarian syndrome (PMOS) and obesity.

Methods

A comprehensive literature search was conducted across scientific databases, including PubMed/MEDLINE, Scopus, and Web of Science, focusing on clinical trials, reviews, and guidelines published between January 2022 and April 2026. Studies evaluating the efficacy, safety, tolerability, and economics aspects of GLP-1 RAs used alone or combined with metformin in obese PMOS phenotypes were systematically analyzed.

Results

GLP-1 RAs demonstrate favorable clinical efficacy compared to conventional lifestyle modifications and metformin in reducing body weight and visceral adiposity. By addressing the adipose-androgen crosstalk and mitigating low-grade chronic inflammation, GLP-1 RAs improve insulin sensitivity and reduce compensatory hyperinsulinemia. This metabolic optimization promotes increased hepatic sex hormone-binding globulin (SHBG) synthesis and decreased circulating free testosterone levels, facilitating the restoration of regular menstrual cycles and spontaneous ovulation. Combination therapy of GLP-1 RAs with metformin yields robust synergistic effects, though consideration of higher treatment costs is warranted. Due to limited definitive data on fetal safety during early pregnancy exposure, a strict pre-pregnancy washout period remains mandatory.

Conclusion

GLP-1 RAs offer a promising, multisystemic therapeutic strategy for the preconception management of PMOS with obesity, effectively breaking the cycle of insulin resistance and hyperandrogenemia. While providing profound metabolic and reproductive benefits, strict adherence to preconception discontinuation protocols is essential. Future large-scale randomized controlled trials are required to further clarify optimal dosing, long-term safety, and definitive gestational outcomes.

Förderung

  • This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors

Zitieren

APA

Karakaya, T. K., & Yılmaz, S. (2026). GLP-1 Receptor Agonists in Preconception Management of Obese Women with Polyendocrine Metabolic Ovarian Syndrome (PMOS): Metabolic and Reproductive Implications. Cerasus Journal of Medicine, 3(2), 157-164. https://doi.org/10.70058/cjm.1924573

Vancouver

Karakaya TK, Yılmaz S. GLP-1 Receptor Agonists in Preconception Management of Obese Women with Polyendocrine Metabolic Ovarian Syndrome (PMOS): Metabolic and Reproductive Implications. Cerasus Journal of Medicine. 2026;3(2):157-164. doi:10.70058/cjm.1924573

BibTeX
@article{Karakaya2026,
  author = {Karakaya, Turan Kaan and Yılmaz, Sercan},
  title = {GLP-1 Receptor Agonists in Preconception Management of Obese Women with Polyendocrine Metabolic Ovarian Syndrome (PMOS): Metabolic and Reproductive Implications},
  journal = {Cerasus Journal of Medicine},
  year = {2026},
  volume = {3},
  number = {2},
  pages = {157--164},
  doi = {10.70058/cjm.1924573}
}
Kostenlos starten →